GERON CORP (GERN) — SEC Financial Statements & Analysis

GERON CORP (GERN) is a pharmaceutical preparations company, incorporated in DE. GERON CORP trades on Nasdaq as: GERN. GERON CORP (GERN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, GERON CORP carries a market cap of $858.49M, a P/E ratio of -12.70x, a P/B ratio of 3.93x, a P/S ratio of 4.20x, an enterprise value of $915.98M, and an EV/EBITDA multiple of -17.86x. On profitability, it posts a gross margin of 124.19%, an operating margin of -25.34%, a net margin of -33.09%, a Return on Equity (ROE) of -28.28%, a Return on Assets (ROA) of -12.59%, and a Return on Invested Capital (ROIC) of -17.72%. Per share, it reports EPS of $-0.10, diluted EPS of $-0.10, free cash flow per share of $-0.17, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 24.61% year-over-year, net income growth of -23.18% year-over-year, and EPS growth of -23.69% year-over-year. On the balance sheet, it maintains a current ratio of 6.92x, a quick ratio of 5.07x, working capital of $416.01M, a debt-to-equity ratio of 1.37x, a debt ratio of 0.58, an interest coverage ratio of -1.71x, free cash flow of $-114.38M (TTM), and net debt of $57.49M. Figures sourced from SEC EDGAR.

Market Cap

$858.49M

P/E TTM

-12.70x

EPS TTM

$-0.10

P/B TTM

3.93x

ROE TTM

-28.28%

ROA TTM

-12.59%

Debt To Equity

1.37x

Free Cash Flow TTM

$-114.38M

Net Revenue TTM Growth 1Y

24.61%

Data as of 2026-06-30 · Source: SEC EDGAR